SHILPAMED Share Price Target 2030

CAGR-based price projection for Shilpa Medicare Limited (SHILPAMED) targeting 2030, derived from official NSE exchange closing prices.

Bear Case (61.3% CAGR)
Rs 7,206
2030 Target
Base Case (153.3% CAGR)
Rs 43,803
2030 Target
Bull Case (704.1% CAGR)
Rs 4,447,945
2030 Target

Current Market Snapshot

CMP: Rs 1,064.10
52W High: Rs 1,070.80
52W Low: Rs 404.05
1Y CAGR: 541.6%
3Y CAGR: 153.3%

Year-by-Year Price Projection

YearBear CaseBase CaseBull Case
2027 Rs 1,717 Rs 2,695 Rs 8,556
2028 Rs 2,769 Rs 6,827 Rs 68,797
2029 Rs 4,467 Rs 17,293 Rs 553,178
2030 Rs 7,206 Rs 43,803 Rs 4,447,945

Other SHILPAMED Price Targets

2025 2026 2027 2028 2035 2040 2050

Frequently Asked Questions

What is the SHILPAMED share price target for 2030?

Based on historical growth analysis, the SHILPAMED share price target for 2030 ranges from Rs 7,206 (conservative) to Rs 43,803 (base case) to Rs 4,447,945 (optimistic). These projections are based on trailing CAGR and should not be treated as guaranteed outcomes.

What is the current share price of SHILPAMED?

The current market price of SHILPAMED (Shilpa Medicare Limited) is Rs 1,064.10. The 52-week high is Rs 1,070.80 and 52-week low is Rs 404.05.

Is SHILPAMED a good stock to buy for the long term?

Long-term investment decisions depend on individual risk tolerance, financial goals, and portfolio diversification. Examine the company's fundamentals, debt-to-equity ratio, promoter holding, and competitive positioning within its sector. BrokerLens provides data-driven analysis; consult a SEBI-registered financial advisor before investing.

What methodology does BrokerLens use for SHILPAMED price targets?

BrokerLens computes price targets using historical Compound Annual Growth Rate (CAGR) derived from official NSE closing prices. Three scenarios are modeled: Bear (conservative at 61.3% CAGR), Base (153.3% CAGR), and Bull (optimistic at 704.1% CAGR). These are statistical projections, not guaranteed forecasts.

Disclaimer: Share price targets on BrokerLens are statistical CAGR projections based on historical NSE closing prices. They are NOT guaranteed outcomes, investment advice, or analyst recommendations. Past performance does not guarantee future results. Consult a SEBI-registered investment advisor before making investment decisions. Mutual fund and equity investments are subject to market risks.